Bourne Lent Asset Management Inc. held its stake in Boston Scientific Corp. (NYSE:BSX) during the second quarter, according to its most recent filing with the SEC. The fund owned 11,104 shares of the company’s stock at the end of the second quarter. Bourne Lent Asset Management Inc.’s holdings in Boston Scientific Corp. were worth $260,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in BSX. PGGM Investments boosted its stake in Boston Scientific Corp. by 192.0% in the second quarter. PGGM Investments now owns 575,120 shares of the company’s stock valued at $13,441,000 after buying an additional 378,168 shares during the period. Strs Ohio boosted its stake in Boston Scientific Corp. by 1,154.5% in the second quarter. Strs Ohio now owns 846,118 shares of the company’s stock valued at $19,773,000 after buying an additional 778,670 shares during the period. Rehmann Capital Advisory Group boosted its stake in Boston Scientific Corp. by 1.9% in the second quarter. Rehmann Capital Advisory Group now owns 11,496 shares of the company’s stock valued at $269,000 after buying an additional 211 shares during the period. Bank of Montreal Can purchased a new stake in Boston Scientific Corp. during the second quarter valued at $13,309,000. Finally, Shell Asset Management Co. boosted its stake in Boston Scientific Corp. by 90.8% in the second quarter. Shell Asset Management Co. now owns 175,658 shares of the company’s stock valued at $4,105,000 after buying an additional 83,606 shares during the period. Institutional investors own 92.06% of the company’s stock.

Boston Scientific Corp. (NYSE:BSX) traded up 1.80% on Wednesday, hitting $23.73. The stock had a trading volume of 6,858,150 shares. Boston Scientific Corp. has a 52 week low of $15.67 and a 52 week high of $24.79. The firm has a 50-day moving average of $23.92 and a 200 day moving average of $22.07. The company’s market capitalization is $32.29 billion.

Boston Scientific Corp. (NYSE:BSX) last released its quarterly earnings results on Thursday, July 28th. The company reported $0.27 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.27. Boston Scientific Corp. had a positive return on equity of 22.66% and a negative net margin of 4.34%. The company had revenue of $2.13 billion for the quarter, compared to analyst estimates of $2.05 billion. During the same period in the previous year, the company posted $0.22 earnings per share. The firm’s revenue was up 15.4% on a year-over-year basis. On average, analysts predict that Boston Scientific Corp. will post ($0.02) earnings per share for the current year.

Several analysts recently commented on BSX shares. Argus upgraded Boston Scientific Corp. from a “hold” rating to a “buy” rating and upped their target price for the company from $23.82 to $33.00 in a report on Thursday, September 1st. They noted that the move was a valuation call. Zacks Investment Research cut Boston Scientific Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, August 31st. Citigroup Inc. upped their target price on Boston Scientific Corp. from $26.00 to $28.00 and gave the company a “buy” rating in a report on Wednesday, August 3rd. Evercore ISI reiterated a “buy” rating and issued a $26.00 target price (up from $25.50) on shares of Boston Scientific Corp. in a report on Sunday, July 31st. Finally, TheStreet cut Boston Scientific Corp. from a “buy” rating to a “hold” rating in a report on Thursday, July 28th. Six equities research analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $25.03.

In other Boston Scientific Corp. news, SVP David A. Pierce sold 2,480 shares of Boston Scientific Corp. stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $24.03, for a total transaction of $59,594.40. Following the completion of the transaction, the senior vice president now owns 28,080 shares in the company, valued at $674,762.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Timothy A. Pratt sold 24,000 shares of Boston Scientific Corp. stock in a transaction on Monday, August 1st. The shares were sold at an average price of $24.46, for a total value of $587,040.00. Following the transaction, the executive vice president now owns 287,495 shares of the company’s stock, valued at approximately $7,032,127.70. The disclosure for this sale can be found here. Corporate insiders own 1.31% of the company’s stock.

Boston Scientific Corp. Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.

5 Day Chart for NYSE:BSX

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corp. (NYSE:BSX).

Receive News & Ratings for Boston Scientific Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.